Physioneal 35 Glucose Clear-Flex 2.27% w/v/22.7mg/ml Malta - English - Medicines Authority

physioneal 35 glucose clear-flex 2.27% w/v/22.7mg/ml

baxter healthcare limited - calcium chloride; glucose monohydrate; magnesium chloride hexahydrate; sodium chloride; sodium hydrogen carbonate; sodium lactate - solution for peritoneal dialysis - calcium chloride 0.343 g/l; glucose monohydrate 33.3 g/l; magnesium chloride hexahydrate 0.051 g/l; sodium chloride 21.12 g/l; sodium hydrogen carbonate 2.1 g/l; sodium lactate 4.48 g/l - blood substitutes and perfusion solutions

Physioneal 35 Glucose Clear-Flex 3.86% w/v/38.6mg/ml Malta - English - Medicines Authority

physioneal 35 glucose clear-flex 3.86% w/v/38.6mg/ml

baxter healthcare limited - calcium chloride; glucose monohydrate; magnesium chloride hexahydrate; sodium chloride; sodium hydrogen carbonate; sodium lactate - solution for peritoneal dialysis - calcium chloride 0.257 g/l; glucose monohydrate 42.5 g/l; magnesium chloride hexahydrate 0.051 g/l; sodium chloride 5.67 g/l; sodium hydrogen carbonate 2.1 g/l; sodium lactate 1.12 g/l - blood substitutes and perfusion solutions

Physioneal 40 Glucose Clear-Flex 1.36%w/v /13.6mg/ml Malta - English - Medicines Authority

physioneal 40 glucose clear-flex 1.36%w/v /13.6mg/ml

baxter healthcare limited - calcium chloride; glucose monohydrate; magnesium chloride hexahydrate; sodium chloride; sodium hydrogen carbonate; sodium lactate - solution for peritoneal dialysis - calcium chloride 0.184 g/l; glucose monohydrate 15 g/l; magnesium chloride hexahydrate 0.051 g/l; sodium chloride 5.38 g/l; sodium hydrogen carbonate 2.1 g/l; sodium lactate 1.68 g/l - blood substitutes and perfusion solutions

Physioneal 40 Glucose Clear-Flex 2.27%w/v/22.7mg/ml Malta - English - Medicines Authority

physioneal 40 glucose clear-flex 2.27%w/v/22.7mg/ml

baxter healthcare limited - calcium chloride; glucose monohydrate; magnesium chloride hexahydrate; sodium chloride; sodium hydrogen carbonate; sodium lactate - solution for peritoneal dialysis - calcium chloride 0.507 g/l; glucose monohydrate 68.85 g/l; magnesium chloride hexahydrate 0.051 g/l; sodium chloride 8.43 g/l; sodium hydrogen carbonate 3.29 g/l; sodium lactate 1.68 g/l - blood substitutes and perfusion solutions

Physioneal 40 Glucose Clear-Flex 3.86%w/v /38.6mg/ml Malta - English - Medicines Authority

physioneal 40 glucose clear-flex 3.86%w/v /38.6mg/ml

baxter healthcare limited - calcium chloride; glucose monohydrate; magnesium chloride hexahydrate; sodium chloride; sodium hydrogen carbonate; sodium lactate - solution for peritoneal dialysis - calcium chloride 0.184 g/l; glucose monohydrate 42.5 g/l; magnesium chloride hexahydrate 0.051 g/l; sodium chloride 5.38 g/l; sodium hydrogen carbonate 2.1 g/l; sodium lactate 1.68 g/l - blood substitutes and perfusion solutions

PHOXILLUM BK4/2.5- calcium chloride, magnesium chloride, sodium chloride, potassium chloride, sodium phosphate, dibasic, and so United States - English - NLM (National Library of Medicine)

phoxillum bk4/2.5- calcium chloride, magnesium chloride, sodium chloride, potassium chloride, sodium phosphate, dibasic, and so

gambro renal products - calcium chloride (unii: m4i0d6vv5m) (calcium cation - unii:2m83c4r6zb, chloride ion - unii:q32zn48698), magnesium chloride (unii: 02f3473h9o) (magnesium cation - unii:t6v3lhy838, chloride ion - unii:q32zn48698), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698), sodium phosphate, dibasic (unii: gr686lba74) (sodium cation - unii:lyr4m0nh37, phosphate i - calcium chloride 0.139 g in 1 l - prismasol and phoxillum solutions are indicated in pediatric and adult patients for use as a replacement solution in continuous renal replacement therapy (crrt) to replace plasma volume removed by ultrafiltration and to correct electrolyte and acid-base imbalances.they may also be used in case of drug poisoning when crrt is used to remove dialyzable substances. none pregnancy category c animal reproduction studies have not been conducted with prismasol and phoxillum solutions. while there are no adequate and well controlled studies in pregnant women, appropriate administration of prismasol and phoxillum solutions with monitoring of fluid, electrolyte, acid-base and glucose balance, is not expected to cause fetal harm, or affect reproductive capacity. maintenance of normal acid-base balance is important for fetal well-being. the components of prismasol and phoxillum solutions are excreted in human milk. appropriate administration of prismasol and phoxillum solutions with monitoring of fluid, electrolyte, acid-

MULTIBIC 3 mmol/L potassium, Solution for Haemofiltration Australia - English - Department of Health (Therapeutic Goods Administration)

multibic 3 mmol/l potassium, solution for haemofiltration

fresenius medical care australia pty ltd - calcium chloride dihydrate,glucose monohydrate,magnesium chloride hexahydrate,potassium chloride,sodium bicarbonate,sodium chloride -

MULTIBIC 2 mmol/L potassium, Solution for Haemofiltration Australia - English - Department of Health (Therapeutic Goods Administration)

multibic 2 mmol/l potassium, solution for haemofiltration

fresenius medical care australia pty ltd - calcium chloride dihydrate,glucose monohydrate,magnesium chloride hexahydrate,potassium chloride,sodium bicarbonate,sodium chloride -

SODIUM VALPROATE WOCKHARDT sodium valproate 1000 mg/10 mL solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

sodium valproate wockhardt sodium valproate 1000 mg/10 ml solution for injection ampoule

wockhardt bio pty ltd - sodium valproate, quantity: 1000 mg - injection, solution - excipient ingredients: dibasic sodium phosphate dodecahydrate; monobasic sodium phosphate dihydrate; phosphoric acid; sodium hydroxide; water for injections - sodium valproate wockhardt is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.

SODIUM VALPROATE WOCKHARDT sodium valproate 400 mg/4 mL solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

sodium valproate wockhardt sodium valproate 400 mg/4 ml solution for injection ampoule

wockhardt bio pty ltd - sodium valproate, quantity: 400 mg - injection, solution - excipient ingredients: dibasic sodium phosphate dodecahydrate; monobasic sodium phosphate dihydrate; phosphoric acid; sodium hydroxide; water for injections - sodium valproate wockhardt is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.